Author

Su‐Fern Tan

University of Virginia Medical CenterORCID 0000-0002-8301-0823Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:ATAC-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

David J. FeithiD· 3 shared Myles C. Cabot· 3 shared Thomas P. LoughraniD· 3 shared Arati K. SharmaiD· 2 shared B. Bishal PaudeliD· 2 shared Charles Edward ChalfantiD· 2 shared David F. ClaxtoniD· 2 shared Francine E. Garrett-BakelmaniD· 2 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

David J. FeithORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia via a cytotoxic integrated stress response

Johnson Ung, Su‐Fern Tan, Jeremy J.P. Shaw, Maansi Taori, Tess M. Deddens, Giovana da Costa Venancio, McLane M. Montgomery, James T. Hagen, Raphael Taiwo Aruleba, Upendarrao Golla, Arati K. Sharma, B. Bishal Paudel, Irene Sung-Ah Lee, Bhavishya U. Ramamoorthy, Kevin A. Janes, , Thomas P. Loughran

This study shows that inhibiting acid ceramidase (AC) enhances venetoclax's effectiveness in venetoclax-resistant AML by inducing a cytotoxic integrated stress response.

bioRxiv · Jun 6, 2025 · PreprintCancer Biology

Acute myeloid leukemia mitochondria hydrolyze ATP to resist chemotherapy

James T. Hagen, McLane M. Montgomery, Raphael Taiwo Aruleba, Brett R. Chrest, Polina M. Krassovskaia, Thomas D. Green, Emely A. Pacheco, Miki Kassai, Tonya N. Zeczycki, Cameron A. Schmidt, Debajit Bhowmick, Su‐Fern Tan, David J. Feith, Charles Edward Chalfant, Thomas P. Loughran, , Kelsey H. Fisher‐Wellman

This study identifies a bioenergetic mechanism in AML cells where mitochondria consume ATP to resist chemotherapy, offering a target for improving treatment.

Science Advances · Apr 9, 2025Peer-reviewedCancer Biology

Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes

B. Bishal Paudel, Su‐Fern Tan, Todd E. Fox, Johnson Ung, Upendarrao Golla, Jeremy J.P. Shaw, Wendy Dunton, Irene Lee, Wisam A. Fares, Satyam Patel, Arati K. Sharma, Aaron D. Viny, Brian M. Barth, Martin S. Tallman, Myles C. Cabot, , Thomas P. Loughran

This study identifies two sphingolipidomic subtypes in AML, with one subtype associated with poor clinical outcomes and high-risk features.

Blood Advances · Jan 3, 2024Peer-reviewedSystems Biology